GPA protects the nigrostriatal dopamine system by enhancing mitochondrial function

Neurobiology of Disease

Volumn 43, Issue 1, 2011, Pages 152-162

  Horvath, Tamas L ^a   Erion, Derek M ^a   Elsworth, John D ^a   Roth, Robert H ^a   Shulman, Gerald I ^a   Andrews, Zane B ^a,b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MONASH UNIVERSITY   (Australia)

Author keywords

AMPK; Dopamine; Ghrelin; Mitochondrial biogenesis; Mitochondrial volume; Nucleator; Stereology

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; GUANIDINOPROPIONIC ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOGENESIS; BRAIN TISSUE; CELL LOSS; CONTROLLED STUDY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DOPAMINERGIC NERVE CELL; DOPAMINERGIC SYSTEM; DRUG EFFICACY; ELECTRON MICROSCOPY; ENZYME ACTIVITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMMUNOHISTOCHEMISTRY; MALE; MITOCHONDRIAL RESPIRATION; MOUSE; NEUROPROTECTION; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; STEREOLOGY;

ADMINISTRATION, ORAL; ANIMALS; CORPUS STRIATUM; DOPAMINE; GUANIDINES; MALE; MICE; MICE, INBRED C57BL; MITOCHONDRIA; NEUROPROTECTIVE AGENTS; PARKINSONIAN DISORDERS; PROPIONIC ACIDS; SUBSTANTIA NIGRA; UP-REGULATION;

EID: 79955958928     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2011.03.005     Document Type: Article

References (68)

1. Abbott R.D., et al. Midlife adiposity and the future risk of Parkinson's disease. Neurology 2002, 59:1051-1057.
2. Abizaid A., et al. Ghrelin modulates the activity and synaptic input organization of midbrain dopamine neurons while promoting appetite. J. Clin. Invest. 2006, 116:3229-3239.
3. Abou-Sleiman P.M., et al. Expanding insights of mitochondrial dysfunction in Parkinson's disease. Nat. Rev. Neurosci. 2006, 7:207-219.
4. Aguirre J.A., et al. A stereological study on the neuroprotective actions of acute modafinil treatment on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced nigral lesions of the male black mouse. Neurosci. Lett. 1999, 275:215-218.
5. Ahmad S.O., et al. Effects of endurance exercise on ventral tegmental area neurons in the chronic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and probenecid-treated mice. Neurosci. Lett. 2009, 450:102-105.
6. Andrews Z.B., et al. Mitochondrial uncoupling proteins in the CNS: in support of function and survival. Nat. Rev. Neurosci. 2005, 6:829-840.
7. Andrews Z.B., et al. Ghrelin promotes and protects nigrostriatal dopamine function via a UCP2-dependent mitochondrial mechanism. J. Neurosci. 2009, 29:14057-14065.
8. Andrews Z.B., et al. Uncoupling protein-2 is critical for nigral dopamine cell survival in a mouse model of Parkinson's disease. J. Neurosci. 2005, 25:184-191. [erratum appears in J Neurosci. 2005 Feb 23;25(8):table of contents].
9. Andrews Z.B., et al. UCP2 mediates ghrelin's action on NPY/AgRP neurons by lowering free radicals. Nature 2008, 454:846-851.
10. Andrews Z.B., et al. Uncoupling protein-2 promotes nigrostriatal dopamine neuronal function. Eur. J. Neurosci. 2006, 24:32-36.
11. Bachmann C.G., Trenkwalder C. Body weight in patients with Parkinson's disease. Mov. Disord. 2006, 21:1824-1830.
12. Baur J.A., et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature 2006, 444:337-342.
13. Bergeron R., et al. Chronic activation of AMP kinase results in NRF-1 activation and mitochondrial biogenesis. Am. J. Physiol. Endocrinol. Metab. 2001, 281:E1340-E1346.
14. Bournival J., et al. Protective effects of resveratrol and quercetin against MPP(+)-induced oxidative stress act by modulating markers of apoptotic death in dopaminergic neurons. Cell. Mol. Neurobiol. 2009.
15. Burke R.E., et al. Neonatal hypoxic-ischemic or excitotoxic striatal injury results in a decreased adult number of substantia nigra neurons. Neuroscience 1992, 50:559-569.
16. Canto C., et al. AMPK regulates energy expenditure by modulating NAD+metabolism and SIRT1 activity. Nature 2009, 458:1056-1060.
17. Chao J., et al. Dietary oxyresveratrol prevents parkinsonian mimetic 6-hydroxydopamine neurotoxicity. Free Radic. Biol. Med. 2008, 45:1019-1026.
18. Chaturvedi R.K., et al. Impaired PGC-1alpha function in muscle in Huntington's disease. Hum. Mol. Genet. 2009, 18:3048-3065.
19. Clark I.E., et al. Drosophila pink1 is required for mitochondrial function and interacts genetically with parkin. Nature 2006, 441:1162-1166.
20. Conti B., et al. Uncoupling protein 2 protects dopaminergic neurons from acute 1,2,3,6-methyl-phenyl-tetrahydropyridine toxicity. J. Neurochem. 2005, 93:493-501.
21. Culmsee C., et al. AMP-activated protein kinase is highly expressed in neurons in the developing rat brain and promotes neuronal survival following glucose deprivation. J. Mol. Neurosci. 2001, 17:45-58.
22. Dasgupta B., Milbrandt J. Resveratrol stimulates AMP kinase activity in neurons. Proc. Natl Acad. Sci. U.S.A. 2007, 104:7217-7222.
23. Dauer W., Przedborski S. Parkinson's disease: mechanisms and models. Neuron 2003, 39:889-909.
24. Dong W., et al. Resveratrol attenuates ischemic brain damage in the delayed phase after stroke and induces messenger RNA and protein express for angiogenic factors. J. Vasc. Surg. 2008, 48:709-714.
25. Dorph-Petersen K.A., et al. Stereological analysis of the mediodorsal thalamic nucleus in schizophrenia: volume, neuron number, and cell types. J. Comp. Neurol. 2004, 472:449-462.
26. Ekstrand M.I., et al. Progressive parkinsonism in mice with respiratory-chain-deficient dopamine neurons. Proc. Natl Acad. Sci. U.S.A. 2007, 104:1325-1330.
27. Gandhi S., et al. PINK1-associated Parkinson's disease is caused by neuronal vulnerability to calcium-induced cell death. Mol. Cell 2009, 33:627-638.
28. Gispert S., et al. Parkinson phenotype in aged PINK1-deficient mice is accompanied by progressive mitochondrial dysfunction in absence of neurodegeneration. PLoS ONE 2009, 4:e5777.
29. Greer E.L., Brunet A. Different dietary restriction regimens extend lifespan by both independent and overlapping genetic pathways in C. elegans. Aging Cell 2009, 8:113-127.
30. Greer E.L., et al. An AMPK-FOXO pathway mediates longevity induced by a novel method of dietary restriction in C. elegans. Curr. Biol. 2007, 17:1646-1656.
31. Hattingen E., et al. Phosphorus and proton magnetic resonance spectroscopy demonstrates mitochondrial dysfunction in early and advanced Parkinson's disease. Brain 2009.
32. Hu G., et al. Type 2 diabetes and the risk of Parkinson's disease. Diabetes Care 2007, 30:842-847.
33. Hu G., et al. Body mass index and the risk of Parkinson disease. Neurology 2006, 67:1955-1959.
34. Jager S., et al. AMP-activated protein kinase (AMPK) action in skeletal muscle via direct phosphorylation of PGC-1alpha. Proc. Natl Acad. Sci. U.S.A. 2007, 104:12017-12022.
35. Jin F., et al. Neuroprotective effect of resveratrol on 6-OHDA-induced Parkinson's disease in rats. Eur. J. Pharmacol. 2008, 600:78-82.
36. Kuramoto N., et al. Phospho-dependent functional modulation of GABA(B) receptors by the metabolic sensor AMP-dependent protein kinase. Neuron 2007, 53:233-247.
37. Larsen S.D., et al. Synthesis and biological activity of analogues of the antidiabetic/antiobesity agent 3-guanidinopropionic acid: discovery of a novel aminoguanidinoacetic acid antidiabetic agent. J. Med. Chem. 2001, 44:1217-1230.
38. Li J., et al. Neuroprotective effects of adenosine monophosphate-activated protein kinase inhibition and gene deletion in stroke. Stroke 2007, 38:2992-2999.
39. Liang C.L., et al. Mitochondria mass is low in mouse substantia nigra dopamine neurons: implications for Parkinson's disease. Exp. Neurol. 2007, 203:370-380.
40. Long J., et al. Grape extract protects mitochondria from oxidative damage and improves locomotor dysfunction and extends lifespan in a Drosophila Parkinson's disease model. Rejuvenation Res. 2009, 12:321-331.
41. Lopez-Lluch G., et al. Mitochondrial biogenesis and healthy aging. Exp. Gerontol. 2008, 43:813-819.
42. Lu K.T., et al. Neuroprotective effects of resveratrol on MPTP-induced neuron loss mediated by free radical scavenging. J. Agric. Food Chem. 2008, 56:6910-6913.
43. Lunardi G., et al. The creatine transporter mediates the uptake of creatine by brain tissue, but not the uptake of two creatine-derived compounds. Neuroscience 2006, 142:991-997.
44. Macaya A., et al. Apoptosis in substantia nigra following developmental striatal excitotoxic injury. Proc. Natl Acad. Sci. U.S.A. 1994, 91:8117-8121.
45. Marongiu R., et al. Mutant Pink1 induces mitochondrial dysfunction in a neuronal cell model of Parkinson's disease by disturbing calcium flux. J. Neurochem. 2009, 108:1561-1574.
46. McCullough L.D., et al. Pharmacological inhibition of AMP-activated protein kinase provides neuroprotection in stroke. J. Biol. Chem. 2005, 280:20493-20502.
47. Meglasson M.D., et al. Antihyperglycemic action of guanidinoalkanoic acids: 3-guanidinopropionic acid ameliorates hyperglycemia in diabetic KKAy and C57BL6Job/ob mice and increases glucose disappearance in rhesus monkeys. J. Pharmacol. Exp. Ther. 1993, 266:1454-1462.
48. Moller A., et al. Efficient estimation of cell volume and number using the nucleator and the disector. J. Microsc. 1990, 159:61-71.
49. Palacino J.J., et al. Mitochondrial dysfunction and oxidative damage in parkin-deficient mice. J. Biol. Chem. 2004, 279:18614-18622.
50. Park J., et al. The PINK1-Parkin pathway is involved in the regulation of mitochondrial remodeling process. Biochem. Biophys. Res. Commun. 2009, 378:518-523.
51. Przedborski S., et al. Transgenic mice with increased Cu/Zn-superoxide dismutase activity are resistant to N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity. J. Neurosci. 1992, 12:1658-1667.
52. Raval A.P., et al. Resveratrol mimics ischemic preconditioning in the brain. J. Cereb. Blood Flow Metab. 2006, 26:1141-1147.
53. Reznick R.M., Shulman G.I. The role of AMP-activated protein kinase in mitochondrial biogenesis. J. Physiol. 2006, 574:33-39.
54. Reznick R.M., et al. Aging-associated reductions in AMP-activated protein kinase activity and mitochondrial biogenesis. Cell Metab. 2007, 5:151-156.
55. Sauer H., Oertel W.H. Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine: a combined retrograde tracing and immunocytochemical study in the rat. Neuroscience 1994, 59:401-415.
56. Schapira A.H., et al. Mitochondrial complex I deficiency in Parkinson's disease. Lancet 1989, 1:1269.
57. Song D.D., et al. Enhanced substantia nigra mitochondrial pathology in human alpha-synuclein transgenic mice after treatment with MPTP. Exp. Neurol. 2004, 186:158-172.
58. Sonsalla P.K., et al. Inhibition of striatal energy metabolism produces cell loss in the ipsilateral substantia nigra. Brain Res. 1997, 773:223-226.
59. St-Pierre J., et al. Suppression of reactive oxygen species and neurodegeneration by the PGC-1 transcriptional coactivators. Cell 2006, 127:397-408.
60. Stichel C.C., et al. Mono- and double-mutant mouse models of Parkinson's disease display severe mitochondrial damage. Hum. Mol. Genet. 2007, 16:2377-2393.
61. Tsai S.K., et al. Resveratrol neuroprotective effects during focal cerebral ischemia injury via nitric oxide mechanism in rats. J. Vasc. Surg. 2007, 46:346-353.
62. Vaillancourt V.A., et al. Synthesis and biological activity of aminoguanidine and diaminoguanidine analogues of the antidiabetic/antiobesity agent 3-guanidinopropionic acid. J. Med. Chem. 2001, 44:1231-1248.
63. Williams D.B., et al. Muscle-specific differences in the response of mitochondrial proteins to beta-GPA feeding: an evaluation of potential mechanisms. Am. J. Physiol. Endocrinol. Metab. 2009, 296:E1400-E1408.
64. Wu Z., et al. Mechanisms controlling mitochondrial biogenesis and respiration through the thermogenic coactivator PGC-1. Cell 1999, 98:115-124.
65. Yousuf S., et al. Resveratrol exerts its neuroprotective effect by modulating mitochondrial dysfunctions and associated cell death during cerebral ischemia. Brain Res. 2009, 1250:242-253.
66. Zhang L., et al. Mitochondrial localization of the Parkinson's disease related protein DJ-1: implications for pathogenesis. Hum. Mol. Genet. 2005, 14:2063-2073.
67. Zheng B., et al. PGC-1alpha, a potential therapeutic target for early intervention in Parkinson's disease. Sci. Transl. Med. 2010, 2:52ra73.
68. Zong H., et al. AMP kinase is required for mitochondrial biogenesis in skeletal muscle in response to chronic energy deprivation. Proc. Natl Acad. Sci. U.S.A. 2002, 99:15983-15987.